表紙
市場調査レポート

むちゃ食い障害:パイプライン製品分析

Binge Eating Disorder - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 283206
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
むちゃ食い障害:パイプライン製品分析 Binge Eating Disorder - Pipeline Review, H1 2016
出版日: 2016年04月30日 ページ情報: 英文 46 Pages
概要

むちゃ食い障害は、抑えきれない摂食および結果として生じる体重増加によって特徴づけられる深刻な状態です。むちゃ食い障害の原因は解明されていません。しかし、家族歴、生物学的要素、長期にわたるダイエットおよび心理的問題はリスクを高めます。徴候および症状には、異常に大量の食事の摂取、頻繁な1人での食事、摂食行動が制御できないと感じること、および落ち込みや不安を抱えていることが含まれます。治療には、心理療法、投薬療法および行動療法の減量プログラムなどが用いられます。

当レポートでは、世界におけるむちゃ食い障害治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

むちゃ食い障害の概要

治療薬の開発

  • パイプライン製品の概要

むちゃ食い障害:企業で開発中の治療薬

むちゃ食い障害:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

むちゃ食い障害:企業で開発中の製品

むちゃ食い障害の治療薬開発に従事している企業

  • Heptares Therapeutics Limited
  • Omeros Corporation
  • Opiant Pharmaceuticals, Inc.
  • Polleo Pharma Limited
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

むちゃ食い障害:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

むちゃ食い障害:最近のパイプライン動向

むちゃ食い障害:休止中のプロジェクト

むちゃ食い障害:開発が中止された製品

むちゃ食い障害:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7928IDB

Summary

Global Markets Direct's, 'Binge Eating Disorder - Pipeline Review, H1 2016', provides an overview of the Binge Eating Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Binge Eating Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Binge Eating Disorder
  • The report reviews pipeline therapeutics for Binge Eating Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Binge Eating Disorder therapeutics and enlists all their major and minor projects
  • The report assesses Binge Eating Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Binge Eating Disorder

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Binge Eating Disorder
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Binge Eating Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Binge Eating Disorder Overview
  • Therapeutics Development
    • Pipeline Products for Binge Eating Disorder - Overview
  • Binge Eating Disorder - Therapeutics under Development by Companies
  • Binge Eating Disorder - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Binge Eating Disorder - Products under Development by Companies
  • Binge Eating Disorder - Companies Involved in Therapeutics Development
    • Heptares Therapeutics Limited
    • Omeros Corporation
    • Opiant Pharmaceuticals, Inc.
    • Polleo Pharma Limited
    • Sunovion Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
  • Binge Eating Disorder - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • armodafinil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dasotraline hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naloxone hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Binge Eating Disorder - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Binge Eating Disorder - Recent Pipeline Updates
  • Binge Eating Disorder - Dormant Projects
  • Binge Eating Disorder - Discontinued Products
  • Binge Eating Disorder - Product Development Milestones
    • Featured News & Press Releases
      • Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Binge Eating Disorder, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Binge Eating Disorder - Pipeline by Heptares Therapeutics Limited, H1 2016
  • Binge Eating Disorder - Pipeline by Omeros Corporation, H1 2016
  • Binge Eating Disorder - Pipeline by Opiant Pharmaceuticals, Inc., H1 2016
  • Binge Eating Disorder - Pipeline by Polleo Pharma Limited, H1 2016
  • Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016
  • Binge Eating Disorder - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Binge Eating Disorder Therapeutics - Recent Pipeline Updates, H1 2016
  • Binge Eating Disorder - Dormant Projects, H1 2016
  • Binge Eating Disorder - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Binge Eating Disorder, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top